Cobimetinib for BRAF-wild-type or Mutated Histiocytoses
Status:
Active, not recruiting
Trial end date:
2022-06-22
Target enrollment:
Participant gender:
Summary
COBRAH is a randomized double-blind 2-steps controlled superiority trial, with 2 parallel
groups.
Patients will be randomly assigned in a 2:1 ratio to receive Cobimetinib orally or placebo
during the first 12-weeks step, allowing the determination of the primary criteria.